Brian M. Watson - Concepedia

Author

Brian M. Watson

Eli Lilly (United States)ORCID

Also Known As

B. M. WATSON, B. M. Watson, B. WATSON, Brian M. Watson, Brian Watson, Watson, B., Watson, Brian M.

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Pfizer (United States)NAEJA-RGM Pharmaceuticals (Canada)University of British Columbia PAREXEL International (United States)

About

Brian M. Watson is an author at Eli Lilly (United States) specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	881
2	Engineering	3	3	69
3	Humanities	2	2	40
4	Arts	1	1	22
5	Language Studies	1	1	29

Brian M. Watson

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor Patrick C. May, Robert A. Dean, Stephen L. Lowe, Journal of Neuroscience Robust Central ReductionAmyloid-β PeptideNeurochemical BiomarkersPeptide ScienceAmyloid Precursor Protein	2011	365
The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans Patrick C. May, Brian A. Willis, Stephen L. Lowe, Journal of Neuroscience Amyloid βNeurodegenerative DiseasesAmyloid LoweringAlzheimer's DiseaseKey Protease	2015	195
3-Aminoquinazolinediones as a New Class of Antibacterial Agents Demonstrating Excellent Antibacterial Activity Against Wild-Type and Multidrug Resistant Organisms Edmund L. Ellsworth, Tuan P. Tran, Hollis D. Showalter, Journal of Medicinal Chemistry Bioorganic ChemistryAntiparasitic AgentAntibiotic AdjuvantNew SeriesAntimicrobial Chemotherapy	2006	62
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1<i>S</i>,3<i>R</i>)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor Junliang Hao, James P. Beck, John M. Schaus, Journal of Medicinal Chemistry Pharmacological CharacterizationDrug TargetPharmacotherapyExperimental PharmacologyPharmaceutical Chemistry	2019	56
Structure–activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors Tuan P. Tran, Edmund L. Ellsworth, Joseph P. Sanchez, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyAntimicrobial Drug DiscoveryBiochemistryMedicineNatural Sciences	2006	51
Rasta Silanes: New Silyl Resins with Novel Macromolecular Architecture via Living Free Radical Polymerization Craig W. Lindsley, John C. Hodges, Gary F. Filzen, Journal of Combinatorial Chemistry New Silyl ResinsMacromolecular ChemistryEngineeringRasta SilanesOrganic Chemistry	2000	41
Synthesis and SAR of novel histamine H3 receptor antagonists Cynthia D. Jesudason, Lisa S. Beavers, Jeffrey W. Cramer, Bioorganic & Medicinal Chemistry Letters MedicineMechanism Of ActionPharmacological AgentPharmacotherapyPharmacology	2006	41
Urgent Archives: Enacting Liberatory Memory Work Brian M. Watson The American Archivist Critical Race TheoryCognitionDigital ArchiveCultural StudiesJournalism	2022	29
A facile synthesis of substituted 3-amino-1<i>H</i>-quinazoline-2,4-diones Tuan P. Tran, Edmund L. Ellsworth, Brian M. Watson, Journal of Heterocyclic Chemistry	2005	25
“There was Sex but no Sexuality*:” Critical Cataloging and the Classification of Asexuality in LCSH Brian M. Watson Cataloging & Classification Quarterly	2020	25

Page 1